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Introduction: Alzheimer’s disease (AD) is a major threat for the well-being of an
increasingly aged world population. The physiopathological mechanisms of late-onset AD
are multiple, possibly heterogeneous, and not well understood. Different combinations of
variables from several domains (i.e., clinical, neuropsychological, structural, and biochem-
ical markers) may predict dementia conversion, according to distinct physiopathological
pathways, in different groups of subjects.
Methods: We launched the Vallecas Project (VP), a cohort study of non-demented
people aged 70–85, to characterize the social, clinical, neuropsychological, structural,
and biochemical underpinnings of AD inception. Given the exploratory nature of the
VP, multidimensional and machine learning techniques will be applied, in addition to the
traditional multivariate statistical methods.
Results: A total of 1169 subjects were recruited between October 2011 and December
2013. Mean age was 74.4 years (SD 3.9), 63.5% of the subjects were women, and
17.9% of the subjects were carriers of at least one ε4 allele of the apolipoprotein E
gene. Cognitive diagnoses at inclusion were as follows: normal cognition 93.0% and mild
cognitive impairment (MCI) 7.0% (3.1% amnestic MCI, 0.1% non-amnestic MCI, 3.8%
mixed MCI). Blood samples were obtained and stored for future determinations in 99.9%
of the subjects and 3T magnetic resonance imaging study was conducted in 89.9% of
the volunteers. The cohort is being followed up annually for 4 years after the baseline.
Conclusion:We have established a valuable homogeneous single-center cohort which,
by identifying groups of variables associated with high risk of MCI or dementia conversion,
should help to clarify the early physiopathological mechanisms of AD and should provide
avenues for prompt diagnosis and AD prevention.
Keywords: Alzheimer’s disease, cohort study, early detection, mild cognitive impairment, risk factors
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Introduction
Alzheimer’s disease (AD) is a devastating illness affecting more
than 25 million people worldwide (Prince et al., 2013) and pro-
ducing a tremendous personal and societal impact (Wimo et al.,
2013). Despite the important amount of resources conveyed for
drug research, advances in the treatment of AD have been scarce,
which underlines the complexity of the disease and the need of a
better understanding of its etiology and pathogenesis leading from
healthy state to full-blown dementia. The relative failure of the dif-
ferent therapy approaches has reinforced the search for alternative
ways of fighting the disease, particularly prevention (Smith and
Yaffe, 2014). A better understanding of the risk factors, especially
thosemodifiable, and of the earliest biological and clinical signs of
the disease, is crucial in order to implement effective preventative
strategies and future therapies.
Current knowledge understands AD as a continuum process
starting many years before the onset of clearly noticeable symp-
toms (Bateman et al., 2012). A high degree of agreement has been
reached around the different stages of the disease, namely the
preclinical phase (brain changes without symptoms), a prodromal
mild cognitive impairment (MCI) phase, and a final dementia
phase usually lasting 10–15 years, leading to total dependence and,
eventually, patient’s death (Dubois et al., 2010; Albert et al., 2011;
Sperling et al., 2011). In practical terms, of utmost interest is the
recognition of the clinical and biological characteristics of people
that converts from normality to MCI and fromMCI to dementia,
as well as the factors that may accelerate or prevent those transits.
The passage from normality to early, mild signs of cognitive
impairment is difficult to categorize and isolate. A potential fea-
ture appearing during this passage is the so-called “subjective cog-
nitive impairment” (SCI) (Reisberg and Gauthier, 2008), or “sub-
jective cognitive decline” state (Jessen et al., 2014), with prevalence
rates in old people varying from 10 to 60%, depending on age,
setting, and definitions applied (Garcia-Ptacek et al., 2013). Pos-
sibly due to the lack of a precise definition, studies addressing the
conversion from normal cognition (NC) toMCI have been scarce,
with incidence rates varying between 51 and 77 per 1000 person-
years. The most frequently reported risk factors for incident MCI
are higher age, lower education, and hypertension (HTA) (Luck
et al., 2010). Conversion from MCI to dementia has been more
widely studied, with a duration of 7–10 years for theMCI stage and
annualized conversion rates of 8–17 per 100 person-years (Ward
et al., 2013). Cognitive performance, cortical amyloid deposition,
hippocampal atrophy, hypometabolism in the parietotemporal
cortex, and alteration in the cerebrospinal fluid (CSF) levels of
42-aminoacid amyloid beta peptide (Aβ42), tau, and phosphory-
lated tau (p-tau) proteins have been consistently associated with
higher conversion rates from MCI to AD dementia (Brooks and
Loewenstein, 2010; Heister et al., 2011; Barnes et al., 2014). Other
markers or comorbidities (e.g., vascular factors, sleep disturbance)
may also be of relevance in the transitions fromhealthy state toAD
(Dufouil et al., 2005; Frisardi et al., 2010; Osorio et al., 2011).
Clearly, the targets for early AD identification should be the
states of SCI and MCI, along with the characterization of those
subjects with high risk of conversion to dementia. Under a
multicausal model of aging-associated, late-onset, sporadic AD,
multiple markers are expected to be relevant for the detection of
the groups of interest and, therefore, the most cost-effective and
safest procedures should be prioritized. Cognitive and magnetic
resonance imaging (MRI) measures are useful for detecting and
characterizing subjects with SCI and MCI, as well as for identi-
fying those subjects who will develop dementia (Dickerson et al.,
2013) but, in the case of MRI, the cost is high. Determinations
of brain amyloid deposits or CSF markers (Aβ42, tau, and p-
tau proteins) are highly predictive of AD conversion in subjects
with MCI, but the procedures are either expensive [positron
emission tomography (PET)] or uncomfortable (CSF determi-
nation). Blood-based (or peripheral) biomarkers (e.g., Aβ frac-
tions, oxidative stress, and inflammatorymarkers) are particularly
attractive in late-onset AD because they can be comfortably and
inexpensively retrieved. In the last years, promising data have been
published regarding the potential of peripheral biomarkers for
the early diagnosis of AD (Carmona et al., 2013; Mapstone et al.,
2014).
We launched a single-center, longitudinal, cohort study with
yearly evaluations to identify subjects at the initial stages of
AD and to clinically and biologically characterize the transi-
tions between healthy cognition, SCI, MCI, and AD dementia.
The study is focused on cognitive testing, comorbidities (par-
ticularly vascular factors, sleep disturbance, and medications),
multi-modal MRI, and systematic blood collection. The objective
is twofold: first, to identify a high risk profile for developing
cognitive impairment and AD in cognitively healthy old people
and, second, to shed light on the multiple mechanisms that may
lead from healthy cognition to dementia in that segment of the
population. This strategy should facilitate, in the mid-term, the
testing of disease modifying therapies and, next, the treatment of
the populations at risk, before they become cognitively impaired
or demented.
Materials and Methods
Design
Single-center, observational, 4-year longitudinal standardized
study, with yearly assessments.
Subjects
Volunteers were recruited through radio and TV campaigns,
leaflet distribution, and visits of the research team to social centers
for the elderly.
The inclusion criteria were as follows: (1) community-dwelling
individuals; (2) both sexes; (3) from 70 to 85 years of age; (4)
able to manage and independent life without any mental disorder
(cognitive or psychiatric) impeding daily functioning; (5) with
reasonable expectation of survival at a 4-year period, operational-
ized as absence of any severe disease at recruitment; and (6) signed
informed consent.
The exclusion criteria were as follows: (1) dementia or severe
cognitive deterioration, operationalized as Mini Mental State-
ment Examination (MMSE) (Folstein et al., 1975) below 24 and
functional activities questionnaire (FAQ) (Pfeffer et al., 1982)
scores below 6 at the baseline assessment; (2) history of neu-
rological disease with clinically relevant impact on cognition
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(e.g., cerebrovascular disease); (3) severe psychiatric disorder;
(4) incidental structural brain findings with impact on cognitive
impairment or survival (e.g., malignant brain tumor); (5) pres-
ence of a severe systemic disease (e.g., cancer under treatment,
malignant hypertension, etc.); and (6) problems for understanding
spoken or written Spanish language.
It was anticipated that two population groups would be repre-
sented in the cohort: (1) subjectswithout noticeable risk factors for
dementia or AD and (2) subjects with risk factors for dementia or
AD. The following factors were considered: subject or informant
report of cognitive deterioration, MCI, AD in first-degree rela-
tive, vascular risk factors (VRF) (high blood pressure, ischemic
heart disease, atrial fibrillation, diabetes, dyslipidemia, obesity,
smoking, stroke), and low education level, intellectual activity, or
socioeconomic class. The presence of any of the four first factors
or a combination of at least two of the other factors was required to
consider a participant as carrier of risk for dementia or AD. The
assumption was that the sample would be evenly distributed for
each group.
Sample Size
Age interval of 70–85 years was chosen aiming at a balance
between high incidence of dementia and survival at a 4-year
follow-up horizon. Under 70 years of age, the incidence of demen-
tia is around 0.6% per year (Hebert et al., 1995), hence requiring
the recruitment of a considerable number of cognitively healthy
participants for observing a significant number ofMCI or demen-
tia conversions. At the opposite end of the study target age, the
risk of mortality for the population between 85 and 90 years of
age increased in average around 15 per 1000 per year (Spanish
National Institute of Statistics estimations for 2008) (National
Institute of Statistics, 2014), which would cause a considerable
attrition of the sample.
At initial setup of the study, population aged 70–85 was
around 4,845,000 persons in Spain, with the following distribu-
tion: 70–74 years, 38.4%; 75–79 years, 34.5%; 80–85 years, 24.4%;
and 85 years, 2.7%. Assuming a similar distribution for the study
population and considering the incidence figures from previous
investigations (Hebert et al., 1995; McDowell, 2001; Kukull et al.,
2002; Bermejo-Pareja et al., 2008a) it was calculated that 20–21
new cases of dementia, including 13–15 cases of AD, would be
diagnosed per 1000 person-years. These figures should increase
over time, as the cohort becomes older during the 4-year follow-
up, and also considering the conversion of a proportion of those
participants who will present MCI at baseline. Since attrition of
the sample was calculated as around 5% per year, a sample of
1200 participants was estimated to observe 100 cases of incident
dementia, including 75 cases of AD at the fourth year of follow-up.
For that sample size and a foreseen incidence of MCI of 2–4% in
the 70-to 85-year-old population (Mielke et al., 2014), conversion
from NC to MCI is expected to occur in over 150 subjects. These
figures were considered sufficient for the study of the potential
markers and risk factors.
Assessments
The general procedure of the Vallecas Project (VP) is shown
in Figure 1. After participants consent, inclusion and exclusion
FIGURE 1 | General procedure and different parts of the study visit of
the Vallecas Project.
criteria are checked and the baseline assessment visit is conducted.
Sociodemographic data, vital signs, and blood samples are col-
lected first, followed by neuropsychological, medical, and MRI
assessment. The complete study visit is usually carried out in a
single day, with convenient breaks. The total duration for the study
visit is 4 h.
Sociodemographic Assessment
Subject demographic and family data, as well as data regard-
ing lifestyle, subjective well-being, and quality of life (QoL) are
completed by the participants themselves, with assistance from
the investigators when needed. The sociodemographic variables
were elaborated ad hoc, after reviewing the main epidemiological
studies regarding lifestyle and AD (Table 1).
Vital Signs and Morphometry
Blood pressure (seated and standing), height andweight, and head
and waist circumferences are measured by a nurse during all the
study visits.
Medical and Neurological Assessment
A semi-structured medical interview, focused on VRF, neurolog-
ical disorders, psychiatric disorders, current medications, family
history of dementia, and sleep habits is conducted by a neu-
rologist, followed by a medical and neurological exam, which
includes some brief motor tasks (Podsiadlo and Richardson, 1991;
Ashendorf et al., 2009) (Table 1).
Neuropsychological Assessment
It includes a comprehensive neuropsychological battery (Table 1)
designed to assess the following cognitive domains, which
are relevant for MCI or dementia diagnosis: processing
speed (Wechsler, 1997) visual and verbal episodic memory
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TABLE 1 | Sociodemographic, clinical, and neuropsychological variables collected in the study visit.
Variable group Variable VISITa
1 2 3 4 5
Sociodemographic Demographic data Race, sex, marital status, number of children, living situation, socioeconomic status, place of residence, occupation, education, number
of siblings, ages of parents when the subject was born
Lifestyle Eating and sleep habits, social relationships and free time, physical activity, expectations, beliefs
Quality of life and
subjective well-being
Movement, self-care, routines, pain/discomfort, anxiety/depression, past and current subjective well-being
Nursing Vital signs and
morphology
Blood pressure (seated and standing), height and weight measures, head and waist circumference
Medical and
neurological
Medical interview Educational achievement and handedness
Vascular risk factors and vascular diseases (present or past): hypertension, hypotension, diabetes, carbohydrate intolerance,
hypercholesterolemia, hypertriglyceridemia, smoking, overweight/obesity, myocardial infarction/angina, atrial fibrillation, other cardiac
diseases, stroke or transient ischemic attack, Hachinski scale
Secondary causes of cognitive deficit (present or past): alcohol, drugs, toxics and nutritional deficits, mental health problems (including
anxiety and depression), head injury, neurological diseases (cerebrovascular episodes, headache, movement disorder, epilepsy,
infection, inflammation, tumors, neuromuscular disorders, toxic and deficiency diseases, development delay, pain)
General medical and surgical anamnesis, particularly looking for disorders that could produce cognitive dysfunction (thyroid disorders,
hepatic failure, renal failure, obstructive sleep apnea syndrome, etc.)
Sleep habits and disorders
Reproductive history (women)
Current treatments (pharmacological and non-pharmacological)
Vision and hearing problems
Cognitive symptoms (attention, orientation to place, immediate memory, delayed memory, visual recognition, dysphasia, executive
dysfunction, dyspraxia)
Neuropsychiatric symptoms (hallucinations, delusions, agitation, depression, anxiety, irritability, disinhibition, euphoria, apathy, aberrant
motor behavior, sleep and night-time behavior change, appetite, eating change)
Physical symptoms (falls, tremor, loss of consciousness, gait abnormality, urinary incontinence, seizures, focal neurological symptoms)
Family history Number and current age (or age of the death) of first-degree relatives and age at onset of neurological or psychiatric illness
Medical examination Heart auscultation
Neurological examination (cranial nerves, motor system, sensory system, osteotendinous and primitive reflexes, cerebellum, gait)
Timed “up-and-go” test and finger tapping test
Neuropsychological Cognitive
performance
Reading test for estimation of intelligence
Mini mental state examination
Free and cued selective reminding test
Clock drawing test
Fonetic verbal fluency (P, M, R)
Semantic verbal fluency (animals, fruits and vegetables, kitchen tools)
Digit-symbol coding of the wechsler adult intelligence scale (WAIS-III)
Rey–Osterrieth complex figure test
Digit span forward and backward of the WAIS-III
Symbolic gesture and bilateral imitation of postures of the revised Barcelona test
Rule shift cards of the behavioral assessment of dysexecutive syndrome
Five point test
Boston naming test (15-item version)
(Continued)
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(Rey, 1941; Osterrieth, 1944; Buschke, 1984; Peña-Casanova
et al., 2009a), executive functions (Regard et al., 1982; Lee et al.,
1994; Peña-Casanova, 2005), language (Peña-Casanova et al.,
2009b), and visuospatial and visuoconstructive skills (Rey, 1941;
Osterrieth, 1944; Lee et al., 1994; Cacho et al., 1999). The battery
is also expected to be sensible for the detection of future cognitive
changes in the specific cognitive domains. In addition, scales
of subjective memory complaints (Sunderland et al., 1984),
mood (Yesavage et al., 1982–1983), anxiety (Spielberger et al.,
1970), and informant-based functional scales (Pfeffer et al., 1982;
Morris, 1993) are administered. The neuropsychological battery
is administered by neuropsychologists.
Laboratory
In order to maximize the chances for biomarker discovery, three
types of evacuated blood collection tubes for serum, plasma, and
blood cells are obtained at each study visit by trained technologists
using a butterfly connected to a vacuum tube holder. In all cases,
blood samples are processed within 1 h of procurement by stan-
dard procedures. From these procedures, eight different fractions,
namely whole blood, serum, platelet-rich plasma, platelet-poor
plasma, buffy coat, red blood cells, mononuclear blood cells,
and genomic DNA are obtained and kept in duplicate aliquots
at  80°C. Genotyping of apolipoprotein E (APOE) polymor-
phisms (rs429358 and rs7412) is performed by real-time PCR
(Calero et al., 2009). Additionally, in order to define homogenous
groups and refine performance of biomarkers, several polymor-
phisms clearly associated to AD are studied by using TaqMan®
probes, namely, BIN1 (rs744373), CLU (rs11136000), ABCA7
(rs3764650), CR1 (rs3818361), and PICALM (rs3851179).
Neuroimaging
All studies are carried out in a 3-T MRI (Signa HDxt GEHC,
Waukesha, WI, USA) equipped with a gradient system of
50mT/m. A phased array eight channels brain coil is used for
all the subjects. The VP protocol includes a structural study with
T1 sequences for volumetry and FLAIR and T2* sequences to
assess white matter (WM) lesions and microhemorrages. Perfu-
sion studywith arterial spin labeling (ASL) technique is conducted
to check for functional alterations and diffusion tensor imaging
(DTI) study is performed for analysis of the anisotropy of WM.
In addition, the DTI sequence permits to measure structural
connectivity. Finally, the VP neuroimaging protocol includes a
resting state functional study with blood oxygen level dependent
(BOLD) sequences (rs-fMRI) to analyze functional connectivity.
Magnetic resonance imaging acquisition parameters are as
follows:
– 3DT1 sequence: 3D FSPGR with IR preparation (TR 10ms,
TE 4.5ms, TI 600ms). FOV 240mm, matrix 288 288, slice
thickness 1mm.
– FLAIR: axial 2D FSE IR (TR 9000ms, TE 130ms, TI 2100ms).
FOV 24mm, slice thickness 3.4 cm.
– T2*: axial 2D GRE EPI (TR 3475ms, TE 27ms). FOV 240mm,
matrix 262 192, slice thickness 3mm.
– Perfusion: 3D ASL acquisition with a delay of 2025ms. FOV
240mm, slice thickness 4 cm.
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– DTI: single shot DWI SE-EPI (TR 9200ms, TE 80ms) with a-
value of 800 s/mm2 and 21 gradient directions. FOV 240mm,
matrix 128 128, slice thickness 3mm.
– Rs-fMRI: acquisition without task, 5:10 s (TR 2500ms, TE
27ms). FOV 240mm, matrix 96 96, slice thickness 2.6 cm.
Cognitive Diagnoses at Baseline
After the study visit is completed, one of the following cognitive
diagnoses is given by consensus of neurologist and neuropsychol-
ogist.
– NC. Performance in neuropsychological tests is considered
within the expected range (not inferior to 1.5 SD or 5° per-
centile) for the participant age and education, with or without
cognitive complaints.
– MCI. There are cognitive complaints by participant or infor-
mant, performance on cognitive tests falls below what is
expected (below 1.5 SD or 5° percentile) according to partic-
ipant age and education, and usual activities of daily living
(ADL) are essentially preserved (Winblad et al., 2004). In case
of MCI diagnosis, a type of amnestic (aMCI), non-amnestic
(naMCI), or mixed (i.e., amnestic and non-amnestic) (mMCI)
MCI is further defined, according the participant’s neuropsy-
chological performance.
– Dementia. The diagnosis of dementia is established according
to the fourth edition, text revised, of theDiagnostic and Statisti-
cal Manual of Mental Disorders (DSM-IV-TR) (American Psy-
chiatric Association (APA), 2000). Any patient with dementia
diagnosis at the baseline visit is excluded from the study.
Follow-Up Visits
Participants of the VP are expected to complete one baseline
and four follow-up annual assessment visits. Subjects are con-
tacted by telephone to arrange the next study visit. The above
described baseline assessment is essentially repeated yearly, with
minor modifications as follows: (1) lifestyle questionnaire from
the sociodemographic assessment is not administered at the three
intermediate visits andmedical interview is also shortened, focus-
ing on changes or new medical events since the last assessment
(particularly, new medical conditions, medications, and change
in cognitive symptoms) and (2) the neuropsychological battery is
mildly modified at the follow-up assessments: the Rey–Osterrieth
Complex FigureTest is not administered at twoof the intermediate
visits and somenew tests focusing on language (Kaplan et al., 1983;
Goodglass and Kaplan, 1996; Fernández-Blázquez et al., 2012),
executive (Regard et al., 1982), and visuoespatial functions (Lee
et al., 1994), which may contribute to a more precise diagnosis
of MCI or dementia or to research purposes, are included. A
cognitive diagnosis is conducted after each follow-up visit, using
the methods described for the baseline visit.
If a participant cannot attend a follow-up visit, he/she is invited
to perform a medical interview by phone. This interview is com-
posed of questions regarding new medical conditions or events,
current medications, cognitive symptoms, and a brief mental
status exam (i.e., temporal orientation, memory, and calculation
items of the MMSE), as well as interview with an informant, per-
formance of FAQ, and diagnosis of dementia according to DSM-
IV-TR (American Psychiatric Association (APA), 2000). Finally,
the participant is encouraged to remain into the study and return
next year for assessment.
Feedback for Participants
Formal feedback is provided in the form of written reports of
the study visit that participants receive at home. These reports
include general results of neuropsychological tests andMRI study
and, if clinically relevant, results from the nursing and medical
and neurological assessments. Furthermore, if any procedure of
the VP reveals findings requiringmedical or psychiatric attention,
the subject is referred to the appropriate assistance resource or is
contacted by telephone to provide information about the finding
and the steps to follow.
Data Analysis
In addition to descriptive statistics, such as central tendency and
distribution methods, the comparisons will be analyzed with the
Student’s t-test for paired and unpaired populations, ANOVA
for one factor, and ANOVA for repeated measures or Wilcoxon,
Mann–Whitney, and Kruskal–Wallis tests if variables do not meet
assumptions for the use of parametric methods. Analyses of asso-
ciation will be carried out by means of correlation coefficients
(Pearson, Spearman, Kendall) and linear and logistic regression.
Predictors will be explored with multiple regression models. Sur-
vival analysis and Cox proportional hazards models for time unit,
considering the conversion to dementia as the event of interest,
will be built. Logistic regression models controlled by age (as a
linear variable) and sex will be used to calculate adjusted odds
ratio (OR) and 95% confidence intervals (CI) for the different
variables of interest (i.e., potential predictors of MCI or dementia
conversion, e.g., APOE, VRF, MRI variables, etc.). Deviations
from normality of quantitative variables will be checked by the
Kolmogorov–Smirnov statistic with Lilliefors’ significance. The
statistical packages IBM SPSS Statistics (IBM Corp., Armonk,
NY, USA), R (R Foundation for Statistical Computing, Vienna,
Austria), and Stata (StataCorp LP, College Station, TX, USA) will
be used.
Given the exploratory nature of the VP, multidimensional
statistics and machine learning methods will be also applied to
the produced data. Three types of analyses will be carried out,
which will allow any kind of inference (diagnostic, predictive,
intercausal, and abductive):
– Longitudinal data clustering, with the aim of identifying sub-
jects with similar behavior over time. Adaptations of partitional
clustering (e.g., K-means) and probabilistic clustering (e.g.,
finite mixture models) for longitudinal data will be developed
for covering this analysis.
– Predictive models, with the aim of predicting the time period
where MCI arises and also when this evolves toward demen-
tia. Pattern recognition techniques, such as classification trees,
Bayesian classifiers, K-nearest neighbors, logistic regression,
support vector machines, and ensembles of classifiers, will be
adapted to the special characteristics of the data set.
– Correlation models, based on dynamic probabilistic graphical
models, able to capture the dependence relationships among
all types of variables (genetic, phenotypic, environmental, neu-
roimaging, clinical, etc.).
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Ethic Aspects
The study was approved by the Ethics Committee of the Carlos III
Institute of Health and the participants signed informed consent
before inclusion.
Results
A total of 2077 subjects contacted the study secretariat during the
recruitment period (i.e., October 2011 toDecember 2013), but 864
of them were discarded before evaluation because they were not
interested in the study or clearly met some of the study exclusion
criteria (Figure 2). One of the most frequent reasons for study
exclusion at that point was the presence of metallic prostheses,
pacemaker, or other body metals. To circumvent that obstacle for
recruitment, a paper document was designed ad hoc, which the
volunteers had to provide, signed by the doctor who implanted
the metal prosthesis, authorizing the performance of 3-T MRI
study. However, that document was only provided in a minority
of the cases. For that reasons, in order to accelerate the inclusion
of subjects, the exclusion criteria of the VP were modified during
the recruitment period, allowing the participation of subjects for
whomMRI was not possible.
Of the remaining 1213 subjects, 44 subjects were discarded
due to the identification of exclusion criteria during the baseline
assessment. Hence, the final number of included and accepted
individuals for follow-up was 1169. The cognitive diagnoses after
the baseline assessment were as follows: NC 93.0%, aMCI 3.1%,
naMCI 0.1%, and mMCI 3.8%. The distribution of the study
subjects and the baseline cognitive diagnoses are summarized in
Figure 2.
All the included subjects were of Caucasian ethnicity and virtu-
ally all of them resided in urban areas of the city of Madrid. Mean
age was 74.4 (SD 3.9, range 70–85 years) and 63.5% of them were
women. Concerning the educative level, 18.6% had not completed
primary school, 32.8% had completed primary education, 24.2%
had completed high school, and 24.4% had achieved university
degree. History of dementia in first-degree relative was present in
20.8% of the subjects (1 relative, 16.7%; 2 relatives, 3.5%, and 3
relatives, 0.6%). Mother was the relative most frequently affected
(progressive dementia was referred in the mother of 11.6% of the
participants).
Vascular risk factors frequently reported in the study cohort.
The most frequent present VRF was HTA (52.7%), followed
by dyslipidemia (51.8%), diabetes mellitus (DM) (11.6%), and
tobacco use (5.4%). The respective figures for a history of those
conditions in the past were as follows: 1.5% (HTA), 3.0% (dys-
lipidemia), 2.6% (DM), and 32.2% (tobacco use). Past history of
depression was also rather frequent: 22.2% of the participants
referred 1 episode, 2.9% referred 2 episodes, and 6.7% referred
>2 episodes of past depression. Nevertheless, a majority of par-
ticipants (77.0%) perceived their health as good or very good and
they rated themselves in the mid-to-high strata of socioeconomic
level.
Blood samples were successfully obtained, processed, and
stored from virtually all the included subjects (1168 out of 1169,
99.9%). By contrast, CSF extraction, which was offered as volun-
tary, was rejected by the immense majority of subjects. In fact,
after information to 104 consecutive subjects, only 1 CSF sample
was consented and collected. The usual reasons for spinal tap
rejectionwere lack of interest in CSF procedure or inCSF results at
that moment. For those reasons, the possibility of CSF extraction
was eliminated from the VP.
The frequency of APOE ε4 allele was 17.9%, while the fre-
quency of APOE ε2 was 10.4%. Mild decrease of frequency
of the APOE ε4 allele was observed when the volunteers were
stratified according to age (19.9% for <75 years of age, 14.5% for
FIGURE 2 | Flowchart of subject recruitment and baseline cognitive diagnoses. aMCI, amnestic mild cognitive impairment (MCI); naMCI, non-amnestic MCI;
mMCI, mixed (i.e., amnestic and non-amnestic) MCI; NC, normal cognition.
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75–80 years of age, and 13.3% for >80 years of age) (p= 0.052).
There were no significant differences in the frequency of ε4
regarding sex (19.0% male, 16.9% female, p= 0.399), whereas the
ε2 allele was more frequently observed in men than in women
(13.5 vs. 9.0%, p= 0.022).
Baseline MRI study was successfully obtained in 1051 (89.9%)
of the included participants. Reasons for not conducting the MRI
study in the remaining 118 subjects were as follows: body metals
(85 subjects, 72.0%), claustrophobia (19 subjects, 16.1%), inciden-
tal finding in previous MRI (12 subjects, 10.2%), and not stated
reasons (2 subjects, 1.7%).
Discussion
A single-center cohort study was launched to characterize the
social, clinical, neuropsychological, and biological underpinnings
of late-onset AD inception. A sample of 1171 volunteers,
aged 70–85, was recruited, virtually accomplishing the initially
projected sample of 1200 volunteers (97.9%). Main barriers for
recruitment were lack of motivation from the potential partic-
ipants and contraindication for MRI performance (Figure 2),
which were circumvented by, respectively, intense work of
search of candidates, information and motivation by the study
administrative staff and allowance of study inclusion withoutMRI
performance.
There was a mild predominance of women in the included
subjects (63.5%), but only slightly above the prevalence of women
in the population data of the Community of Madrid provided by
the Spanish National Institute of Statistics (frequency of women
of 58.5% according census data of July 2013) (National Institute
of Statistics, 2014). However, the educational attainment of the
included subjects was high in comparison with the educational
attainment of the Spanish population, but this was obviously the
result of the necessity of literacy for study inclusion. A survey of
people aged 65 ormore from the Community ofMadrid displayed
prevalence of illiteracy of 7.0% and prevalence of more than pri-
mary education of 20.7% (vs. 48.6% in the present study) (Morales
et al., 2004). Then, results derived from the VP might not be gen-
eralizable to people in the low educational strata. Figures regard-
ing prevalence of VRF displayed also some discrepancy, when
compared to previous Spanish surveys (Del Barrio et al., 2007).
Analysis of the APOE gene showed a prevalence of 17.9% for
APOE ε4 allele and a mild descent with increasing age, which is
similar to other previously studied Spanish populations (Calero
et al., 2009) and also consistent with findings from other countries
(Corrada et al., 2013).
A prevalence of MCI of 7% was obtained, which falls within
the range of 3–19% prevalence reported in previous community-
based studies (Busse et al., 2006; Gauthier et al., 2006; Bermejo-
Pareja et al., 2008b; Ravaglia et al., 2008; Petersen et al., 2010).
Interestingly, virtually, all the cases of MCI presented mem-
ory impairment, in contrast with balanced (Busse et al., 2006;
Ravaglia et al., 2008) or only mildly disbalanced (Manly et al.,
2005; Petersen et al., 2010) prevalence of aMCI and naMCI in
previous studies. Our clear predominance of aMCI might be due
to selection bias related with good health status (thus lowering the
possibility of vascular naMCI) or tomethodological issues (under-
representation or less sensibility of non-memory tests in the base-
line assessment). Nevertheless, the predominance of aMCImay be
considered positive for the objectives of the VP, since high risk of
futureAD is expected inMCIwhenmemory is impaired (Petersen
et al., 2009).
Determination of AD biomarkers in the CSF was rejected by
the participants of the VP. This is in contrast with previous
investigations with very high success of CSF consecution (Weiner
et al., 2010). This was certainly due to the optional nature of
CSF study, but also old age, cultural aspects, or difficult logistics
(patients who were interested in the study of CSF biomarkers were
referred to a partner hospital) could have contributed. By contrast,
blood extraction was fully accepted by the participants and blood
samples were successfully collected in virtually all the subjects
(99.9%). In addition, the achievement of multi-modal MRI study
was high (89.9%). These blood and MRI materials, which are
expected to be also longitudinally collected, along with the con-
comitant social, clinical, and neuropsychological data of the VP,
should provide insight in the physiopathological underpinnings
of AD and should help to accurately detect the subjects at risk and
to provide new avenues for the prevention of this complex and
burdensome disease.
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